Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Dornase alfa

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Aug 03, 2027 · 340 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dornase alfa (Desoxyribonuclease), ATC R05CB13

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice explicitly says the contract documents must be submitted via the DTVP communication area and not via the off...

Contract conclusion is only possible until 03.08.2027, and monthly start dates depend on receipt of complete documents...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Non-exclusive open-house rebate agreement for Dornase alfa (Desoxyribonuclease), ATC R05CB13.
  • Supply of pharmaceutical products under a predefined rebate contract.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical supply arrangement by AOK Bayern for Dornase alfa (Desoxyribonuclease), ATC R05CB13, not a competitive award procedure in the usual sense. The model is non-exclusive and open to all pharmaceutical companies that meet the stated suitability requirement. No contract value is provided. Submission is possible electronically with a qualified electronic signature via DTVP or in paper form in duplicate originals. The deadline for contract conclusion is 03.08.2027, with monthly entry dates depending on when complete documents are received.

Ryzyka

The notice explicitly says the contract documents must be submitted via the DTVP communication area and not via the off...

Contract conclusion is only possible until 03.08.2027, and monthly start dates depend on receipt of complete documents...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • The signed contract and the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Dornase alfa

Open-house non-exclusive rebate agreement for the medicinal product Dornase alfa (Desoxyribonuclease), ATC R05CB13. The lot is for pharmaceutical products and is described as a supply arrangement. The notice states that the contract conditions are predefined and not individually negotiable. Source: structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Sep 2025 - Sep 2027

Kategoria

Pharmaceutical products

Termin

Deadline Aug 03, 2027

Szczegóły zamówienia

Data publikacji
13 Aug 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
533448-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30